Glibenclamide - Biogen

Drug Profile

Glibenclamide - Biogen

Alternative Names: CIRARA; Diabeta; Glybenclamide; Glyburide for injection; RP-1127

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Remedy Pharmaceuticals
  • Developer Biogen; Ohio State University; Remedy Pharmaceuticals
  • Class Antihyperglycaemics; Benzamides; Small molecules; Sulfonylureas
  • Mechanism of Action ABCC8 protein antagonists; TRPM cation channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Stroke
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain injuries; Spinal cord injuries; Stroke

Most Recent Events

  • 15 May 2017 Biogen acquires Glibenclamide from Remedy Pharmaceuticals
  • 17 Jan 2017 Remedy Pharmaceuticals receives Orphan Drug status for Stroke (Cerebral oedema) in USA
  • 08 Jun 2016 Glibenclamide - Remedy Pharmaceuticals receives Fast Track designation for Stroke [IV,Injection] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top